This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2026 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.86% per year. These returns cover a period from January 1, 1988 through February 2, 2026. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View the Zacks #1 Rank List
medical-devices: Archive
Stryker Introduces SmartHospital Platform to Advance Connected Care
by Zacks Equity Research
SYK unveils SmartHospital Platform to link devices, data and care teams, aiming to boost hospital efficiency, clinical decisions and digital transformation.
SYKNegative Net Change ISRGNegative Net Change PAHCPositive Net Change GEHCNegative Net Change
medical medical-devices
Hims and Hers Expands Consumer-Focused Digital Health Platform
by Debanjana Dey
HIMS expands its digital care platform with new specialties, lab testing and global moves as it scales personalized telehealth services.
MEDPositive Net Change HIMSPositive Net Change TEMNegative Net Change
medical medical-devices
GEHC Wins FDA 510(k) Approval for View, Enhances Radiology Workflows
by Zacks Equity Research
GE HealthCare wins FDA 510(k) clearance for View, a cloud-native imaging viewer in Genesis Radiology Workspace aimed at improving radiology workflows.
ISRGNegative Net Change CAHNegative Net Change PAHCPositive Net Change GEHCNegative Net Change
medical medical-devices
Key Catalysts That Will Likely Drive Prospects for NPCE Stock in 2026
by Indrajit Bandyopadhyay
NPCE heads into 2026 with 20%+ RNS growth targets, higher Medicare reimbursement and a cleaner revenue mix as the DIXI distribution business rolls off.
MDTNegative Net Change LIVNNegative Net Change NPCEPositive Net Change
medical medical-devices
NPCE RNS System Explained: Growth Drivers and Setup for 2026
by Indrajit Bandyopadhyay
NPCE enters 2026 with rising RNS adoption, stronger margins and Medicare payment hikes that could boost hospital economics for replacement procedures.
MDTNegative Net Change LIVNNegative Net Change NPCEPositive Net Change
medical medical-devices
NeuroPace's Seizure ID and New Indication Could Expand RNS Demand
by Indrajit Bandyopadhyay
NPCE's Seizure ID AI tool and potential idiopathic generalized epilepsy approval could expand RNS adoption as NeuroPace pushes software-driven care in 2026.
MDTNegative Net Change LIVNNegative Net Change NPCEPositive Net Change
medical medical-devices
Here's Why You Should Retain CONMED Stock in Your Portfolio Now
by Zacks Equity Research
CNMD's growth rests on AirSeal, Buffalo Filter and BioBrace as supply chains normalize, even as tariffs and a GI exit pressure EPS.
CNMDNegative Net Change ISRGNegative Net Change ALGNNegative Net Change CAHNegative Net Change
medical medical-devices
Alector (ALEC)'s Technical Outlook is Bright After Key Golden Cross
by Zacks Equity Research
Should investors be excited or worried when a stock's 50-day simple moving average crosses above the 200-day simple moving average?
ALECPositive Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
5 Medical Instruments Stocks to Buy Amid Huge Short-Term Price Upside
by Nalak Das
ISRG, GMED, EW, ALC and IRMD show strong short-term upside as AI tools, acquisitions and new product pipelines fuel growth.
ISRGNegative Net Change EWPositive Net Change ALCNegative Net Change GMEDNegative Net Change IRMDNegative Net Change
medical-devices
What Drives Hologic's GYN Surgical Strength in a Competitive Market?
by Moumi Mondal
HOLX expands its GYN Surgical reach with MyoSure, NovaSure and Gynesonics boost as the global women's health devices market grows and minimally invasive demand rises.
JNJPositive Net Change MDTNegative Net Change HOLXNegative Net Change
medical medical-devices